Caprion Will Use CellCarta to Help Vertex Pharma Discover Biomarkers
Vertex Pharmaceuticals will rely on data from Caprion Pharmaceuticals' CellCarta proteomics platform as part of a biomarker-discovery collaboration, Caprion said this week.
As part of the deal, Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and pre-clinical studies conducted by Vertex.
Caprion's platform profiles proteins and provides protein expression and identification in tissues and blood plasma.
Financial terms of the agreement were not disclosed.
UCD Conway Institute Licenses Nonlinear Dynamics' 2D Gel Analysis Software
Nonlinear Dynamics said this week that Dublin's UCD Conway Institute of Biomolecular and Biomedical Research has purchased multiple licenses of its Progenesis PG240 2D gel analysis software
Progenesis PG240 includes Nonlinear's SameSpots technology, which the company said improves the accuracy of 2D gel analysis.
Financial terms were not disclosed.
BG Medicine, Mitsubishi Pharma Partner on Biomarker Discovery for Muscle Toxicity
BG Medicine said this week that it has signed a collaborative research agreement with Mitsubishi Pharma of Osaka, Japan, to discover biomarkers associated with muscle toxicity in lipid-lowering compounds.
BG Medicine said it will use proteomics, metabolomics, and computational analyses to study the molecular effects of selected lipid-lowering agents on skeletal muscle and to identify specific plasma biomarkers of these effects.
Mitsubishi Pharma will contribute transcript, clinical chemistry, and histopathology data to the project.
BG Medicine said that it will jointly own "certain rights" to the project data and biomarkers with Mitsubishi Pharma, but additional terms of the agreement were not disclosed.
BD Biosciences, Dynomics Partner for Leukemia, Lymphoma Dx Development
BD Biosciences has partnered with Dutch diagnostics shop Dynomics to develop tests for leukemia and lymphoma, BD said this week.
BD now has an exclusive worldwide license to specific intellectual property related to the flow cytometry detection of fusion proteins, the company said.
William Rhodes, president of cell analysis at BD Biosciences, said that the partnership will give "BD the opportunity to advance technical solutions that can be applied in [its] core markets of ASR and reagent components used in leukemia and lymphoma testing."
Financial terms were not disclosed.
PerkinElmer to Supply NCGC With Reagents, Tech, and Manpower
PerkinElmer said this week it will provide reagents, instrumentation, and scientific support for the National Institute of Health's Chemical Genomics Center.
Under the terms of the deal, NCGC gets access to PerkinElmers AlphaScreen, Lance, and Delfia technologies as well as the company's assay and protocol researchers.
PerkinElmer's remuneration was not released.
ABI/MDS Sciex to Sell ACD/Labs Products
Advanced Chemistry has signed a resellers agreement with Applied Biosystems and MDS Sciex.
Under the agreement, ABI/MDS Sciex will sell ACD/Labs' MS Manager, MS Fragmenter, and ChemSketch software in combination with ABI/MDS Sciex mass spectrometry products worldwide.
Financial details were not provided.
Protein, DNA-Analysis Shop Deltadot Raises $10.4M in VC Round
Deltadot has raised £6 million ($10.4 million) in a round of venture capital financing, the company said this week.
The company will use the cash to increase production capacity of its recently launched Peregrine and Merlin systems; develop an international sales and marketing force; and develop a protein-folding/-unfolding chip for drug discovery and QA/QC applications, and a "virtual" 2D chip to "replace" 2D gels.
Major participants in the financing round included existing investors FF&P Private Equity Limited, which led the round; Imperial Innovations; and NPI Ventures; as well as new investors London Technology Fund and Sitka Health Fund.
Deltadot, based in London, develops and sells tools for protein and nucleic-acid analysis through the use of its Label Free Intrinsic Imaging technology, the company said.